Clinical Trial Update: An Extension Study of WA19926 of the Long-Term Safety of Tocilizumab (RoActemra/Actemra) in Patients With Early Moderate to Severe Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

An extension study reports the long-term safety data for tocilizumab in patients with early moderate to severe rheumatoid arthritis. Completed phase 3 trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• RoActemra (tocilizumab)
• Tocilizumab (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2023-12-11